FBXW7 and cancer: Our work highlights the use of a well-studied inhibitor of the ATR kinase for use in cancers harboring loss-of-function mutations in FBXW7, which expands the pool of patients who could respond well to this treatment outside of those with mutations in core DNA damage response genes who are currently being included in clinical trials.